CONTINUING MEDICAL EDUCATION INFORMATION
 
Race Against the Clock: Overcoming Challenges in the Management of Anticoagulant-Associated Intracerebral Hemorrhage
 
Release Date: August 1, 2014
Last Review: October 25, 2013
Expiration Date: July 31, 2015
Estimated Time to Complete this CME Activity: 1.5 hours
Media/Method of Participation: Journal Article, Web-based posttest, and evaluation
Hardware/Software Requirements: Any Web browser

*This activity expired for credit on July 31, 2015 and is no longer available for credit
 
TARGET AUDIENCE
This activity has been designed to meet the educational needs of neurosurgeons, residents, fellows, neurosurgical nurses, and physician assistants interested in the practice and business of neurosurgery.
 
STATEMENT OF NEED
Neurosurgeons are intimately involved in the emergency management of anticoagulant-treated patients who present with an intracerebral hemorrhage requiring urgent correction of their coagulopathy to prevent worsening hemorrhage and to facilitate surgical intervention as necessary. A number of therapies have been used alone or in combination for the treatment of anticoagulant-associated intracerebral hemorrhage (AAICH) to reverse anticoagulation in order to achieve hemodynamic stability, limit hematoma expansion, and prepare the patient for potential neurologic surgery. Given the essential role of the neurosurgeon, in consult with the emergency department physician, in managing these patients, this enduring activity will elucidate warfarin reversal strategies (and related current controversies) with available and soon-to-be-available therapies for the management of AAICH, and the importance of timely intervention in order to achieve successful reversal of warfarin-induced coagulopathy.
 
EDUCATIONAL OBJECTIVES
Upon proper completion of this enduring material, participants should be better able to:
  • Appropriately apply evidence-based guidelines and strategies to the management of patients with warfarin-associated ICH.
  • Recognize the barriers to successful management of patients with ICH in the context of anticoagulation-associated coagulopathy.
  • Based on risk/benefit analysis of reversal agents, select appropriate therapies for the treatment of patients with AAICH.
     
FACULTY
Peter Le Roux, MD, FACS
Professor of Neurosurgery
Thomas Jefferson University
Philadelphia, PA
Co-Director, Brain and Spine Center
Lankenau Medical Center
Wynnewood, PA
 
Charles V. Pollack, Jr, MA, MD, FACEP
Professor
Department of Emergency Medicine
Perelman School of Medicine
University of Pennsylvania
Chairman, Department of Emergency Medicine
Pennsylvania Hospital
Philadelphia, PA

SCIENTIFIC DIRECTORS:
Melissa Milan, MD
Alisa Schaefer, PhD
 
ACCREDITATION STATEMENT
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
CREDIT DESIGNATION STATEMENT
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
The American Association of Neurological Surgeons accepts these AMA PRA Category 1 CreditsTM toward the Continuing Education Award in Neurosurgery to maintain membership in the AANS and toward the ABNS Maintenance of Certification program.

In collaboration with the Hospital Quality Foundation.                         
 
INSTRUCTIONS FOR OBTAINING CREDIT
To receive a CME certificate of participation, participants must:
  • Read the entire publication, including the Continuing Medical Education information.
  • Register or log in at www.paradigmmc.com/JNSpub to complete and submit the online posttest and evaluation OR complete the posttest/evaluation form at the end of the article and mail or fax it to Paradigm Medical Communications, LLC, 523 Route 303, Orangeburg, NY 10962; fax (845) 398-5108.
  • Answer 70% of the posttest questions correctly to earn credit. Online completion of the posttest allows unlimited opportunities to successfully complete the posttest.
 
Following online completion of the posttest and evaluation, a certificate of participation will be available for download/printing immediately. Participants who submit a posttest/evaluation form via mail or fax will receive an email with a link to their certificate of participation within 1 to 2 weeks following receipt of completed form.
 
For additional questions regarding CME credit, please contact the CME Department of Paradigm Medical Communications, LLC,at (845) 398-5946.
 
DISCLOSURE OF COMMERICAL SUPPORT
This CME activity is supported by an educational grant from CSL Behring.
 
DISCLOSURES
In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
 
Peter Le Roux, MD, FACS
Retained Consultant: Integra LifeSciences; Codman & Shurtleff, Inc.; Synthes, Inc.
Speakers Bureau: Integra LifeSciences
Contracted Research: Integra LifeSciences
 
Charles V. Pollack, Jr, MA, MD, FACEP
Consultant: Astra-Zeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb; Daiichi Sankyo, Inc; Janssen Pharmaceuticals, Inc; Pfizer Inc; Sanofi-Aventis U.S. LLC.
 
Scientific Directors, Melissa Milan, MD, and Alisa Schaefer, PhD have no financial conflicts to disclose.
 
Paradigm Medical Communications, LLC staff members have no financial conflicts to disclose.

Sean D. Lavine, MD-Independent Peer Reviewer
Director, Endovascular Neurosurgery
Columbia Presbyterian Medical Center
New York, NY
Secretary, AANS/CNS Executive Council of Cerebrovascular Surgery
No financial conflicts to disclose.
 
Jack E. Ansell, MD-Independent Peer Reviewer
Professor of Medicine
Hofstra North Shore/LIJ
School of Medicine
New York, NY
Advisory Board: Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb; Daiichi Sankyo, Inc; Janssen Pharmaceuticals, Inc; Perosphere Inc; Pfizer Inc
Shareholder: Perosphere Inc
 
RESOLUTION OF CONFLICTS OF INTEREST
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each continuing medical education activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
 
DISCLAIMER
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
 
Terms of Use and Privacy Policy
Disclaimer
The information presented in this activity is for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented in this article are solely those of the Faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information in this article should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC is committed to protecting the privacy of those who participate in the activities (herein referred to as "website") located at www.paradigmmc.com. The paragraphs below describe the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
To earn CME credits using the website, the submission of certain personally identifiable information is necessary. The required items include: first name, last name, degree, and e-mail address. These items are necessary to award and track the credits participants may earn after completing the program. Participants are required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and assists the staff of Paradigm Medical Communications, LLC in continuously improving the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participant credits.
 
Contact Us
If you have any questions or comments regarding this policy, please send e-mail to contactus@paradigmmc.com.